Stock Market & Financial Investment News

News Breaks September 28, 2012 06:36 EDT ONCY Oncolytics Biotech appoints Dr. Alan J. Tuchman as Chief Medical Officer Oncolytics Biotech announced the appointment of Dr. Alan Tuchman to the role of Chief Medical Officer and SVP, Clinical and Medical Development. Dr. Tuchman holds a B.S. from the City College of New York, an M.D. from the University of Cincinnati, College of Medicine and an MBA from the Columbia University, School of Business. Throughout his medical career he has held numerous academic and administration appointments at a variety of medical schools in the New York area and is currently Clinical Professor of Neurology at the New York Medical College in Valhalla, New York, and engaged in the private practice of neurology. Dr. Tuchman also brings substantial capital markets experience to this new role. He spent nearly four years as a sell-side analyst with Oscar Gruss & Son, advancing to the role of Senior Vice President, Equity Research. News For ONCY From The Last 14 Days Check below for free stories on ONCY the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 22, 2013 07:35 EDT ONCY Bloom Burton & Co. to host a conference Subscribe for More Information 06:36 EDT ONCY Oncolytics Biotech meets primary endpoint for first stage of U.S. Phase 2 trial Oncolytics Biotech announced preliminary results from its U.S. Phase 2 clinical trial in patients with metastatic melanoma using intravenous administration of Reolysin in combination with carboplatin and paclitaxel. The study is a two stage design. Up to 18 evaluable patients with metastatic melanoma were to be treated in the first stage. If three or more patients demonstrated a partial response, or PR, or better, the study could then proceed to the second stage, with up to 43 patients being treated in the entire study. This endpoint was met after 14 evaluable patients were enrolled. Three of 14 patients exhibited a PR, and an additional seven patients had stable disease, or SD, for a disease control rate of 71.5%. Sign up for a free trial to see the rest of the stories you've been missing.